Rnl Bio Co., Ltd.

Other

R Bio Co., Ltd.

Rmedica Co., Ltd.

K-Stemcell Co., Ltd.

Rnl Life Science Ltd.

Naturecell Co., Ltd.

Ra, Jeong Chan

Jeong Chan Ra

Sung Keun Kang

Eun-Young Kim

Kyung Sun Kang

Il Seob Shin

Byeung Gie Kim

Hang Young Lee

Hyeong Geun Park

Hyuk Joon Kwon

Young Ho Kim

Hyoeun Kim

Yun Jung Kim

Seob Shin

Jae Wook Huh

Jung Youn Jo

Huu Tung Nguyen

Hyo Eun Kim

Sang Kyu Woo

Jung Ran Park

Seok Hyon You

Sun Jin Baek

Ju Yeon Seo

Mi Sook Lee

Sung-Min Kim

Soon Ae Kwon

Jin Hwa Lee

Sang Kuy Woo

The present invention relates to a method of culturing mesenchymal stem cells using gamma-irradiated serum, and more particularly to a method for culturing mesenchymal stem cells, which can improve the adhesion and proliferation rate of stem cells using a medium containing gamma-irradiated serum and an antioxidant. The method for culturing mesenchymal stem cells according to the present invention can restore the adhesion and proliferation rate of stem cells when culturing the stem cells using gamma-irradiated FBS, which is safe from contamination sources but reduces the efficiency of adhesion and proliferation of the cells. Thus, the inventive method is useful for the production of stem cells for cell therapy.

Method for culturing mesenchymal stem cells using gamma-irradiated serum

Disclosed are a medium composition for culturing mesenchymal stem cells for the treatment of cancer which can inhibit proliferation of cancer cells, while maintaining differentiation capability and activity thereof, and a method for producing mesenchymal stem cells for the treatment of cancer using the composition. More particularly, disclosed are a medium composition containing vitamin C and aspirin for producing mesenchymal stem cells having improved inhibitory activity against proliferation of cancer cells, and a method for producing mesenchymal stem cells for the treatment of cancer using the composition.

Method for producing mesenchymal stem cells that inhibit proliferation of cancer cells

The present invention relates to a method for preparing stem cells having a size suitable for intravascular administration, and preferably to a method for preparing stem cells with a diameter ranging from 11-16 &#x3bc;m. Additionally, the present invention relates to media composition for preparing stem cells having a size suitable for intravascular administration. According to the present invention, stem cells having a size suitable for intravascular administration can be prepared such that stem cells administered into a vein can stably reach a target tissue, and thus can more efficiently increase efficacy displaying activity, thereby innovatively enhancing the efficacy of cell therapy using stem cells.

Method for manufacturing stem cell having appropriate size for intravascular administration

The present disclosure relates to a medium composition for culturing stem cells, and more specifically, to a medium composition for culturing mesenchymal stem cells, in which the medium composition includes a basic medium in which various quasi-completed mediums (DMEM, &#x3b1;-MEM, IMDM, F12, and DMEM/F12) are mixed, L-ascorbic acid 2-phosphate, fetal bovine serum, basic fibroblast growth factors (b-FGF), insulin, N-acetyl-L-cysteine, calcium chloride, and hydrocortisone. According to the present disclosure, it is capable of improving proliferation ability and differentiation ability of the mesenchymal stem cells, and is capable of producing cell therapy products more economically using the mesenchymal stem cells by enabling the mesenchymal stem cells to be cultured at a low price compared to the existing culturing methods.

Medium composition for culturing stem cells

The present invention relates to a composition capable of improving storage stability of stem cells. More specifically, the present invention relates to a composition which contains a serum or a plasma for improving cold storage stability of stem cells. The composition for improving storage stability of stem cells according to the present invention can maintain a survival rate of over 90% for at least 9 days without changes in the properties, the number or the size of the stem cells, and thus is useful in the long-term transport of stem cells for cell therapy and the preparation of cell therapeutics injection products having an excellent effect.

Composition for improving stability of stem cells

An integrated kit for separating blood and concentrating PRP includes: (a) a main body that includes an upper storage portion, a lower storage portion, and a passage portion for connecting the upper storage portion and the lower storage portion; (b) a upper cover coupled to an upper end of the upper storage portion; (c) an inner stopper inserted into a lower end of the lower storage portion so as to seal the lower storage portion; (d) a closing adjustment screw which can move vertically while penetrating a hole formed at the inner stopper and seals the passage portion; and (e) a lower cover coupled to an outside of the lower end of the lower storage portion and the outside of the inner stopper to prevent the separation of the closing adjustment screw coupled to the inner stopper in case of centrifugation.

Integrated kit for separating blood and concentrating PRP and method for extracting PRP using the same

The present invention relates to a medium composition for transforming stem cells from an aged person into young stem cells, and more particularly to a medium composition for culturing stem cells, which is used to rejuvenate stem cells from an aged person so as to have characteristics similar to those of the stem cells of young people, and to a method for rejuvenating stem cells, which comprises culturing stem cells from an aged person in the medium composition. According to the present invention, even mesenchymal stem cells collected from over 60 years old patients can be transformed into young mesenchymal stem cells having high differentiation ability, high telomerase activity, and high ability to express stem cell markers. Thus, the present invention can significantly increase the efficacy of cell therapy employing mesenchymal stem cells.

Medium composition for rejuvenating stem cells

There is provided a method for preventing disruption and aggregation of stem cells. In addition, there is provided a stem cell composition for intravascular administration, in which stem cells are suspended in a solution containing aspirin. Further, there is provided a composition for preventing disruption or aggregation of stem cells, in which stem cells are suspended in a solution containing aspirin. According to the present invention, disruption and aggregation of cells may be prevented during transport or storage, such that the administered stem cells may stably reach the target tissue and exhibit the activity thereof in a more efficient manner, thereby remarkably increasing the effect of cell therapy using stem cells.

Method and composition for preventing stem cell disruption and aggregation

The present invention relates to a cellular therapeutic agent for treating urinary incontinence, and more particularly to a cellular therapeutic agent for treating urinary incontinence, which contains stem cells derived from the decidua of the placenta or menstrual fluid or stem cells derived from adipose. The decidua-derived stem cells or adipose-derived stem cells show the effects of increasing leak point pressure and urethral sphincter contractility, and thus are useful as an agent for treating urinary incontinence.

Cellular therapeutic agent for incontinence or urine comprising stem cells originated from decidua or adipose

The present invention relates to a composition for increasing the milk production of livestock, containingas an active ingredient. More specifically, relates to a composition and a feed additive for increasing the milk production of cows, containingas an active ingredient, and a composition and a feed additive for reducing the number of somatic cells in livestock milk, containingas an active ingredient. The composition can increase milk production of animals, and, in addition, can reduce the number of somatic cells in milk being produces, thus enabling production of good quality milk.

[object Object]

The present invention relates to a medium for culturing mesenchymal stem cells, and more particularly to a medium composition for culturing mesenchymal stem cells, which contains basal medium, L-ascorbic acid 2-phosphate, fetal bovine serum, basic fibroblast growth factor (b-FGF), non-essential amino acids (NEAAs), insulin, N-acetyl-L-cysteine, calcium chloride, and hydrocortisone, and a method of culturing mesenchymal stem cells using the same. According to the present invention, a number of mesenchymal stem cells required for stem cell therapy can be obtained in a short time, and the ability of mesenchymal stem cells to differentiate is improved so that they are useful for stem cell therapy.

Culture medium composition for culturing amnion-derived mesenchymal stem cell, and method for culturing amnion-derived mesenchymal stem cell by using same

The present invention relates to the ability of adipose tissue-derived adult stem cells to migrate, and more particularly to the novel use of adipose tissue-derived adult stem cells primed with a specific chemokine or growth factor and their specific secretory products, which more effectively migrate to a disease site in vivo. The inventive composition containing either adipose-derived adult stem cells or adipose tissue-derived adult stem cells primed with a specific chemokine or growth factor can be administered by a simple method such as intravenous administration and are able to induce the targeting of the stem cells to a disease site. Thus, the composition is useful as a cell therapeutic agent.

Method for inducing migration of adipose-derived adult stem cells

The present invention relates to an antiviral composition comprising anextract, more specifically, relates to a method for preparing high activated anti-influenza viral composition, which comprises an extract of the bark or stem of, and an anti-influenza viral composition comprising the extract. An extract of the bark or stem ofaccording to the present invention has low toxicity to normal cells, while having an excellent antiviral effect even when administered at low concentration and thus the composition comprising theextract can be used effectively in preventing and treating influenza viral infection.

The present invention relates to a method for isolating and culturing adult stem cells derived from human amniotic membrane in high yield, and more particularly to a method for obtaining a large amount of adult stem cells, the method comprising obtaining amniotic epithelial cells from human amniotic tissue in high yield by treatment with dithiothreitol (DTT) and a low concentration of trypsin and culturing the amniotic epithelial cells in a medium containing a Rho-associated kinase inhibitor. The human amniotic epithelial cell-derived stem cells are easily extracted compared to existing therapeutic stem cells such as umbilical cord blood stem cells and bone marrow stem cells, the yield and proliferation thereof are significantly increased by DTT treatment, the addition of the ROCK inhibitor or the replacement of medium. Thus, the method can be used to efficiently prepare adult stem cells.

Method for isolating and culturing adult stem cells derived from human amniotic epithelium

The present invention relates to a diaryl hepatonoid-based compound of formula (1) having viral inhibitory activity; its pharmaceutically acceptable salt; or a hydrate, a solvate or a prodrug of any of the foregoing, and a pharmaceutical composition comprising the same, and the use thereof therapeutic agents. The diaryl hepatonoid-based compounds according to present invention have an excellent effect of inhibiting viral activity, and thus will be useful as therapeutic agents against virus-related diseases.

Growing community of inventors

Gyeonggi-do, South Korea

Jeong Chan Ra